$ALLR
Allarity Therapeutics, Inc. Stock $allr

$allr Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023019295 Filed on March 13, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit			-$2.265M
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.232M	$2.245M	$9.962M
YoY Change	-25.92%	-63.91%	-19.4%
% of Gross Profit
Research & Development	$1.427M	$941.0K	$6.930M
YoY Change	10.71%	-90.12%	-51.18%
% of Gross Profit
Depreciation & Amortization	$10.00K	$2.000K	$60.00K
YoY Change	-56.52%	-87.5%	-43.4%
% of Gross Profit
Operating Expenses	$3.659M	$3.186M	$34.46M
YoY Change	-14.95%	-79.76%	29.77%
Operating Profit	-$3.659M		-$34.46M
YoY Change	-80.02%		29.77%
Interest Expense	$92.00K	$3.609M	$12.00K
YoY Change	-99.25%	-4065.93%	-98.8%
% of Operating Profit
Other Income/Expense, Net	$307.0K	$0.00	$16.88M
YoY Change		-100.0%	-1027.18%
Pretax Income	-$3.352M	-$3.141M	-$17.58M
YoY Change	-22.17%	-81.28%	-33.7%
Income Tax		-$303.0K	-$1.521M
% Of Pretax Income
Net Earnings	-$3.352M	-$3.102M	-$16.06M
YoY Change	8.83%	-81.55%	-39.74%
Net Earnings / Revenue
Basic Earnings Per Share	-$4.43		-$2.21
Diluted Earnings Per Share	-$4.43	-$0.28	-$2.21
COMMON SHARES
Basic Shares Outstanding	30.00M shares	10.26M shares	9.527M shares
Diluted Shares Outstanding	758.1K shares		9.527M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$295.0K	$2.080M	$2.080M
YoY Change	-97.97%	-89.39%	-89.39%
Cash & Equivalents	$295.0K	$2.029M	$2.029M
Short-Term Investments		$51.00K	$51.00K
Other Short-Term Assets	$1.067M	$1.559M	$2.017M
YoY Change	-23.57%	1443.56%	1897.03%
Inventory
Prepaid Expenses	$315.0K	$591.0K
Receivables
Other Receivables
Total Short-Term Assets	$2.966M	$4.968M	$4.968M
YoY Change	-82.77%	-76.4%	-76.4%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.00K	$21.00K	$27.00K
YoY Change	-64.79%	-77.66%	-71.28%
Goodwill
YoY Change
Intangibles	$9.711M	$9.549M
YoY Change		-66.06%
Long-Term Investments		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Other Assets
YoY Change
Total Long-Term Assets	$9.736M	$9.576M	$9.576M
YoY Change	-30.85%	-66.49%	-66.49%
TOTAL ASSETS
Total Short-Term Assets	$2.966M	$4.968M	$4.968M
Total Long-Term Assets	$9.736M	$9.576M	$9.576M
Total Assets	$12.70M	$14.54M	$14.54M
YoY Change	-59.41%	-70.7%	-70.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.449M	$6.251M	$6.251M
YoY Change	11.21%	795.56%	795.56%
Accrued Expenses	$2.351M	$1.904M	$1.912M
YoY Change	65.1%	-78.08%	-77.99%
Deferred Revenue
YoY Change
Short-Term Debt	$2.687M	$2.644M	$2.644M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.59M	$11.22M	$11.22M
YoY Change	-8.83%	-45.84%	-45.84%
LONG-TERM LIABILITIES
Long-Term Debt	$1.110M	$1.083M	$1.083M
YoY Change	10.45%	10.62%	10.62%
Other Long-Term Liabilities	-$120.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$1.110M	$1.083M	$1.083M
YoY Change	10.44%	-86.74%	-86.74%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.59M	$11.22M	$11.22M
Total Long-Term Liabilities	$1.110M	$1.083M	$1.083M
Total Liabilities	$13.04M	$12.65M	$12.65M
YoY Change	-9.54%	-58.98%	-58.98%
SHAREHOLDERS EQUITY
Retained Earnings	-$85.90M	-$82.55M
YoY Change		24.15%
Common Stock	$0.00	$2.000K
YoY Change	-100.0%	100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$3.102M	-$113.0K	$1.890M
YoY Change
Total Liabilities & Shareholders Equity	$12.70M	$14.54M	$14.54M
YoY Change	-59.41%	-70.7%	-70.7%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$3.352M	-$3.102M	-$16.06M
YoY Change	8.83%	-81.55%	-39.74%
Depreciation, Depletion And Amortization	$10.00K	$2.000K	$60.00K
YoY Change	-56.52%	-87.5%	-43.4%
Cash From Operating Activities	-$3.201M	-$2.446M	-$16.82M
YoY Change	-44.38%	-45.44%	11.74%
INVESTING ACTIVITIES
Capital Expenditures		$18.00K	$18.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$809.0K
YoY Change	-100.0%		-19.1%
Cash From Investing Activities		-$18.00K	$791.0K
YoY Change			-20.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.158M	1.000M	-$1.311M
YoY Change		-94.58%	-103.88%
NET CHANGE
Cash From Operating Activities	-$3.201M	-2.446M	-$16.82M
Cash From Investing Activities		-18.00K	$791.0K
Cash From Financing Activities	$1.158M	1.000M	-$1.311M
Net Change In Cash	-$2.043M	-1.464M	-$17.34M
YoY Change		-110.49%	-187.7%
FREE CASH FLOW
Cash From Operating Activities	-$3.201M	-$2.446M	-$16.82M
Capital Expenditures		$18.00K	$18.00K
Free Cash Flow		-$2.464M	-$16.84M
YoY Change		-45.04%	11.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent		usd
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
CY2022	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit		usd
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-41160
CY2022	dei	Entity Registrant Name EntityRegistrantName	ALLARITY THERAPEUTICS, INC.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2147982
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	24 School Street
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02108
CY2022	dei	City Area Code CityAreaCode	(401)
CY2022	dei	Local Phone Number LocalPhoneNumber	426-4664
CY2022	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2022	dei	Trading Symbol TradingSymbol	ALLR
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	10592706	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30000000	shares
CY2022	dei	Auditor Firm AuditorFirmId	392
CY2022	dei	Auditor Name AuditorName	Wolf & Company, P.C.
CY2022	dei	Auditor Location AuditorLocation	Boston, MA
CY2022Q4	us-gaap	Cash Cash	2029000	usd
CY2021Q4	us-gaap	Cash Cash	19555000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1559000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	625000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	591000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	36000	usd
CY2021Q4	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent	350000	usd
CY2022Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	789000	usd
CY2021Q4	us-gaap	Income Tax Receivable IncomeTaxReceivable	838000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4968000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	21404000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8000	usd
CY2022Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6000	usd
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	86000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9549000	usd
CY2021Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28135000	usd
CY2022Q4	us-gaap	Assets Assets	14544000	usd
CY2021Q4	us-gaap	Assets Assets	49633000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6251000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	698000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1904000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8590000	usd
CY2022Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	41000	usd
CY2021Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	60000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	374000	usd
CY2021Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	11273000	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	2644000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11222000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	20719000	usd
CY2022Q4	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	1083000	usd
CY2021Q4	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	979000	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	7181000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	349000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	1961000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12654000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	30849000	usd
CY2022Q4	allr	Convertible Preferred Stock ConvertiblePreferredStock	2001000	usd
CY2021Q4	allr	Convertible Preferred Stock ConvertiblePreferredStock	632000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	2003000	usd
CY2021Q4	us-gaap	Redeemable Noncontrolling Interest Equity Preferred Carrying Amount RedeemableNoncontrollingInterestEquityPreferredCarryingAmount	632000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15897845	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15897845	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8096014	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8096014	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83156000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	85243000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-721000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-600000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82550000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66492000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-113000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18152000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14544000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49633000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6930000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14196000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	17571000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9962000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12360000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	34463000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	26556000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34463000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-26556000	usd
CY2022	allr	Proceeds From Sales Of Ip ProceedsFromSalesOfIP	-1780000	usd
CY2021	allr	Proceeds From Sales Of Ip ProceedsFromSalesOfIP	-1005000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000	usd
CY2022	allr	Interests Expense InterestsExpense	-223000	usd
CY2021	allr	Interests Expense InterestsExpense	-499000	usd
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1347000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-115000	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-495000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-913000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-95000	usd
CY2022	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	17125000	usd
CY2021	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	2087000	usd
CY2022	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability	800000	usd
CY2021	allr	Change In Fair Value Of Convertible Debt ChangeInFairValueOfConvertibleDebt	474000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-141000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16884000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	41000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-17579000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-26515000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	133000	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-16058000	usd
CY2021	us-gaap	Profit Loss ProfitLoss	-26648000	usd
CY2022	allr	Deemed Dividend Percentage1 DeemedDividendPercentage1	0.08	pure
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1572000	usd
CY2022	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	3421000	usd
CY2022	allr	Net Loss Attributable To Common Stockholders NetLossAttributableToCommonStockholders	-21051000	usd
CY2021	allr	Net Loss Attributable To Common Stockholders NetLossAttributableToCommonStockholders	-26648000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9527111	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6358988	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16058000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26648000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent	-121000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent	-1966000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16179000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-28623000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	24439000	usd
CY2021	allr	Units Issued For Cash UnitsIssuedForCash	12125000	usd
CY2021	allr	Stock Issued During Fair Value Of Investor Warrants StockIssuedDuringFairValueOfInvestorWarrants	-2000000	usd
CY2021	allr	Stock Issued During Period Value Shares Issued For Cash Exercise Of Warrants StockIssuedDuringPeriodValueSharesIssuedForCashExerciseOfWarrants	2972000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2384000	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-2475000	usd
CY2021	allr	Convertible Debt Conversion And Debt Settlement ConvertibleDebtConversionAndDebtSettlement	2880000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6368000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-1966000	usd
CY2021	allr	Stock Issued During Period Fair Value Of Instrument Specific Credit Risk StockIssuedDuringPeriodFairValueOfInstrumentSpecificCreditRisk	-9000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	75000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26648000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18152000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18152000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	203000	usd
CY2022	allr	Floor Price Liability FloorPriceLiability	-3421000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	954000	usd
CY2022	allr	Deemed Dividend Percentage DeemedDividendPercentage	0.08	pure
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	1572000	usd
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	2000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1752000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-121000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-16058000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-113000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16058000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26648000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1780000	usd
CY2021	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1005000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	60000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	106000	usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	17571000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1752000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	6368000	usd
CY2022	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	138000	usd
CY2021	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	238000	usd
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1347000	usd
CY2022	allr	Lossgain On Investment LossgainOnInvestment	-115000	usd
CY2021	allr	Lossgain On Investment LossgainOnInvestment	-495000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-450000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-95000	usd
CY2021	us-gaap	Extinguishment Of Debt Gain Loss Income Tax ExtinguishmentOfDebtGainLossIncomeTax	141000	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	474000	usd
CY2022	allr	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-17125000	usd
CY2021	allr	Fair Value Adjustment Of Derivative Liabilities FairValueAdjustmentOfDerivativeLiabilities	-2087000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1612000	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	20000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1077000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	330000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	618000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-130000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6207000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1311000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4722000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	7197000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-19000	usd
CY2021	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	8000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-99000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-124000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16817000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14886000	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	809000	usd
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1005000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	791000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1005000	usd
CY2021	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	-84000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	32125000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2765000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2041000	usd
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	1511000	usd
CY2022	allr	Penalty On Series A Preferred Stock Liability1 PenaltyOnSeriesAPreferredStockLiability1	800000	usd
CY2022	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Other Long Term Debt ProceedsFromIssuanceOfOtherLongTermDebt	1140000	usd
CY2021	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	2858000	usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	2945000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1311000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33818000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17337000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19937000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-189000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-680000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19555000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	298000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2029000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19555000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	12000	usd
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	118000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	85000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	262000	usd
CY2022	allr	Gain On Sale Of Ip GainOnSaleOfIP	971000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1667000	usd
CY2021	us-gaap	Stock Issued1 StockIssued1	2880000	usd
CY2021	allr	Conversion Of Derivative Liability To Equity ConversionOfDerivativeLiabilityToEquity	206000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	1157000	usd
CY2021	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	7000	usd
CY2022Q4	us-gaap	Percentage Of Debt Hedged By Interest Rate Derivatives PercentageOfDebtHedgedByInterestRateDerivatives	0.08	pure
CY2022	allr	Deemed8 Dividend On Series A Preferred Shares Deemed8DividendOnSeriesAPreferredShares	1572000	usd
CY2022	allr	Series B Preferred Share Dividend SeriesBPreferredShareDividend	2000	usd
CY2022	allr	Reclassification Of Derivative Liabilities Related To Converted Preferred Stock ReclassificationOfDerivativeLiabilitiesRelatedToConvertedPreferredStock	954000	usd
CY2021	allr	Reclassification Of Derivative Liabilities Related To Converted Preferred Stock ReclassificationOfDerivativeLiabilitiesRelatedToConvertedPreferredStock	75000	usd
CY2021	allr	Noncash Derivative Warrant Liability Costs NoncashDerivativeWarrantLiabilityCosts	2384000	usd
CY2021	allr	Right Of Use Asset Modification RightOfUseAssetModification	145000	usd
CY2022	allr	Aggregate Purchase Price AggregatePurchasePrice	8075824	shares
CY2022	allr	Financial Term FinancialTerm	P1Y
CY2022Q4	us-gaap	Retained Earnings Appropriated RetainedEarningsAppropriated	82600000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(c) Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting years. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the Series A preferred shares, warrants, convertible debt, and the accrual for research and development expenses, fair values of acquired intangible assets and impairment review of those assets, share based compensation expense, and income tax uncertainties and valuation allowances. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering reasonable changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known and if material, their effects are disclosed in the notes to the consolidated financial statements. Actual results could differ from those estimates or assumptions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><i> </i></p>
CY2022	allr	Foreign Exchange Gainloss ForeignExchangeGainloss	121000	usd
CY2021	allr	Foreign Exchange Gainloss ForeignExchangeGainloss	1966000	usd
CY2022Q4	us-gaap	Credit Risk Derivatives At Fair Value Net CreditRiskDerivativesAtFairValueNet	0	usd
CY2021Q4	us-gaap	Credit Risk Derivatives At Fair Value Net CreditRiskDerivativesAtFairValueNet	-9000	usd
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>(e) Concentrations of credit risk and of significant suppliers</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is not significant. The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><i> </i></p>
CY2022Q1	allr	Intangible Assets Utilizing A Discounted IntangibleAssetsUtilizingADiscounted	0.16	pure
CY2022	allr	Estimated Depreciation Period EstimatedDepreciationPeriod	P5Y
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	17571	usd
CY2021	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	usd
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14007000	usd
CY2022Q4	allr	Accrued Liability AccruedLiability	1400	usd
CY2021Q4	allr	Accrued Liability AccruedLiability	5000000	usd
CY2022	allr	Intangible Assets Utilizing A Discounted IntangibleAssetsUtilizingADiscounted	0.26	pure
CY2022	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	3564000	usd
CY2021	allr	Total Proceed TotalProceed	$2,679
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	13.3
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.22	pure
CY2022	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	5500000	dkk
CY2022	us-gaap	Income Tax Reconciliation Minority Interest Income Expense IncomeTaxReconciliationMinorityInterestIncomeExpense	25000000	dkk
CY2022	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	711	usd
CY2021	us-gaap	Income Tax Credits And Adjustments IncomeTaxCreditsAndAdjustments	875	usd
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	6000	usd
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	86000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8000	usd
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	8075824	shares
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.0001
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0.05
CY2022	allr	Exchange Ratio Description ExchangeRatioDescription	The “exchange ratio” means the quotient of the number of Allarity A/S ordinary shares outstanding in Allarity A/S divided by 50 or 0.02 shares of Delaware Common Stock for each Allarity A/S ordinary share issued and outstanding (as defined in the Reorganization Agreement), as of immediately prior to the effective time.
CY2022	us-gaap	Other Expenses OtherExpenses	200000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	98000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	9000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8000	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	107000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	51000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	53000	usd
CY2022Q4	allr	Salary Deposit SalaryDeposit	85000	usd
CY2021Q4	allr	Salary Deposit SalaryDeposit	65000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	82000	usd
CY2021Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	507000	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	81000	usd
CY2022	allr	Deferred Directors Officers Insurance Expense DeferredDirectorsOfficersInsuranceExpense	1260000	usd
CY2022	allr	Net Other Current Asset NetOtherCurrentAsset	1559000	usd
CY2021	allr	Net Other Current Asset NetOtherCurrentAsset	625000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	350000	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	845000	usd
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	235000	usd
CY2022	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-115000	usd
CY2021	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-495000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	350000	usd
CY2022Q4	us-gaap	Area Of Land AreaOfLand	137	sqm
CY2022Q4	allr	Right Of Use Assets Amount RightOfUseAssetsAmount	145000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	104000	usd
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	134000	usd
CY2022Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	9549000	usd
CY2021Q4	us-gaap	Other Indefinite Lived Intangible Assets OtherIndefiniteLivedIntangibleAssets	28135000	usd
CY2022Q4	allr	Development Cost Liability DevelopmentCostLiability	964000	usd
CY2021Q4	allr	Development Cost Liability DevelopmentCostLiability	6750000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	221000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	1088000	usd
CY2022Q4	allr	Accrued Board Member Fees AccruedBoardMemberFees	91000	usd
CY2021Q4	allr	Accrued Board Member Fees AccruedBoardMemberFees	54000	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	239000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	316000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	389000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	382000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1904000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	8590000	usd
CY2022Q2	allr	Principal Amount1 PrincipalAmount1	1000000	usd
CY2022	allr	Noncreditable Upfront Payment NoncreditableUpfrontPayment	1000000	usd
CY2022	allr	Promissory Note PromissoryNote	1000000	usd
CY2022Q4	allr	Interest Payable Percentage InterestPayablePercentage	0.05	pure
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	106000	usd
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	99000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	539000	usd
CY2022Q2	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	441005	shares
CY2022	allr	Issuance Of Warrants Purchased Shares IssuanceOfWarrantsPurchasedShares	2018958	shares
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2021Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1000000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	215000	usd
CY2021Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	263000	usd
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	53000	usd
CY2021	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	48000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	838000	usd
CY2021Q4	us-gaap	Convertible Debt ConvertibleDebt	785000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	194000	usd
CY2021	us-gaap	Interest Expense Other InterestExpenseOther	143000	usd
CY2022	us-gaap	Financing Interest Expense FinancingInterestExpense	51000	usd
CY2021	us-gaap	Financing Interest Expense FinancingInterestExpense	51000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	1083000	usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	979000	usd
CY2022Q4	allr	Principal Amount PrincipalAmount	1667000	usd
CY2022Q4	us-gaap	Payments For Rent PaymentsForRent	1667000	usd
CY2022Q4	us-gaap	Cash Cash	350000	usd
CY2022Q4	us-gaap	Cash Cash	650000	usd
CY2022	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	5000000	usd
CY2022	us-gaap	Debt Instrument Redemption Price Percentage Of Principal Amount Redeemed DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed	0.35	pure
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	34000	usd
CY2022	us-gaap	Interest Expense InterestExpense	12000	usd
CY2022	allr	Contractual Interest ContractualInterest	10000	usd
CY2021	us-gaap	Investment Income Amortization Of Discount InvestmentIncomeAmortizationOfDiscount	2000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	2667000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	-33000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2634000	usd
CY2022Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	10000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	2644000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	10100000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	100000000	sek
CY2020Q1	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	1010000	usd
CY2020Q1	us-gaap	Debt Instrument Convertible Carrying Amount Of The Equity Component DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent	10000000	sek
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9.9061
CY2020Q1	us-gaap	Debt Instrument Description DebtInstrumentDescription	a)Fees payable include 5% of the $10,100 Commitment in 2 equal installments of $252, paid on the disbursement of each of the first and second Tranches; and a further 5% of the principal of the notes is to be deducted from the payment of each Tranche. b)The loan is due for repayment in full 12 months from the date of issuance; or immediately repayable in the event of default, a change of control or a material adverse event. The Investor may in its sole discretion decide to convert the Loan in full or in part (in multiples of $4 (SEK 25) in 1,000’s) into new shares. c) The Conversion Price of the Notes is 95% of the lowest closing volume weighted average price as reported by Bloomberg (“VWAP”) of the shares during the applicable pricing period preceding the conversion date. Conversion of the Loan Amount shall be made at a rate equal to the Conversion Price. The Conversion Price cannot be below par value. The number of new Shares issued by the Company to the Investor upon conversion of the Loan Amount shall be calculated as the Loan Amount divided by the Conversion Price. If the Conversion Price is equal to or less than $0.01 (DKK 0.05), the Investor will not be required to convert such Note. If the Investor (contrary to the clear intention in the Agreement) claims repayment of one or more Tranches and not to convert into Shares the Company shall be entitled to deduct the commitment fee in connection with the repayment. d) Default interest accrues on the overdue amount from the due date up to the date of actual payment at 8% per annum; calculated on a 360-day year and accrues and compounds on a daily basis.
CY2021Q4	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.15	pure
CY2021	allr	Credit Risk Percentage CreditRiskPercentage	0.01	pure
CY2021	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	9000	usd
CY2022	allr	Finance Cost Amount FinanceCostAmount	-474000	usd
CY2021	allr	Finance Cost Amount FinanceCostAmount	141000	usd
CY2020Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	1327000	usd
CY2021Q4	allr	Convertible Debt Issued In The Period ConvertibleDebtIssuedInThePeriod	1140000	usd
CY2021	allr	Servicing Liability At Fair Value Changes In Fair Value Resulting From Changes In Valuation Inputs Or Changes In Assumptions1 ServicingLiabilityAtFairValueChangesInFairValueResultingFromChangesInValuationInputsOrChangesInAssumptions1	474000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	116000	usd
CY2021	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2825000	usd
CY2021Q2	allr	Sale Of Purchase Shares SaleOfPurchaseShares	20000	shares
CY2021Q2	allr	Preferred Shares Value PreferredSharesValue	1000
CY2021Q2	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	20000000	usd
CY2021Q4	allr	Preferred Stock Descriptions PreferredStockDescriptions	we issued 20,000 shares of Series A Preferred Stock at $1,000 per share and a common stock purchase warrant to purchase 2,018,958 shares of common stock at an initial exercise price of $9.9061 to 3i for an aggregate purchase price of $20 million.
CY2021Q3	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	2500000	usd
CY2021Q3	allr	Dividend Equal Percentage DividendEqualPercentage	0.08	pure
CY2021Q3	us-gaap	Shortterm Debt Fair Value ShorttermDebtFairValue	80000	usd
CY2021Q3	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.18	pure
CY2022	us-gaap	Debt Instrument Convertible Threshold Percentage Of Stock Price Trigger DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger	1.25	pure
CY2022Q4	us-gaap	Variable Interest Entity Ownership Percentage VariableInterestEntityOwnershipPercentage	0.0999	pure
CY2022Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	9.906
CY2022	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.18	pure
CY2022Q4	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.18	pure
CY2022Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	1.25	pure
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.02	pure
CY2022Q2	allr	Securities Purchase Agreement Percentage SecuritiesPurchaseAgreementPercentage	0.02	pure
CY2022Q2	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.02	pure
CY2022Q2	allr	Accrue Payments Percent AccruePaymentsPercent	0.02	pure
CY2022	allr	Fund Warrant Terms Description FundWarrantTermsDescription	(i)The warrants have a term of three years and expire on December 20, 2024; (ii)The exercise of the warrants are subject to a beneficial ownership limitation of 4.99% which can be adjusted to a beneficial ownership limitation of 9.99% upon 61 days’ prior written notice
CY2022Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	7801831	shares
CY2022	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	954000	usd
	us-gaap-sup	Dividend Income Operating Paid In Cash DividendIncomeOperatingPaidInCash	1511000	usd
CY2022Q3	us-gaap-sup	Dividend Income Operating Paid In Cash DividendIncomeOperatingPaidInCash	1646000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	121018	shares
CY2022Q4	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice	264000	usd
CY2022Q1	us-gaap	Trading Securities Cost TradingSecuritiesCost	2500000	usd
CY2022Q1	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.08	pure
CY2022Q1	us-gaap	Convertible Preferred Stock Converted To Other Securities ConvertiblePreferredStockConvertedToOtherSecurities	1572	usd
CY2022Q4	us-gaap	Registration Payment Arrangement Accrual Carrying Value RegistrationPaymentArrangementAccrualCarryingValue	800000	usd
CY2021Q4	us-gaap	Assets Under Management Carrying Amount AssetsUnderManagementCarryingAmount	154000	usd
CY2021Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities	7181000	usd
CY2022	allr	Changeinfairvalue1 Changeinfairvalue1	-6227000	usd
CY2022	allr	Amount Transferred To Equity AmountTransferredToEquity	-954000	usd
CY2021	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	7409000	usd
CY2021	allr	Changeinfairvalue1 Changeinfairvalue1	-153000	usd
CY2021	allr	Amount Transferred To Equity AmountTransferredToEquity	-75000	usd
CY2021Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities	7181000	usd
CY2021	allr	Fair Value Per Warrant Issuable FairValuePerWarrantIssuable	363
CY2022Q4	us-gaap	Limited Liability Company Llc Preferred Unit Issuance Value LimitedLiabilityCompanyLLCPreferredUnitIssuanceValue	0	usd
CY2021	allr	Warrants Of Series WarrantsOfSeries	176	shares
CY2021Q2	allr	Granted To Investors Shares GrantedToInvestorsShares	482250	shares
CY2021Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	2384000	usd
CY2021Q4	allr	Warrants Shares WarrantsShares	274386	shares
CY2021Q2	allr	Probability Weighted Value Of To3 Warrants ProbabilityWeightedValueOfTO3Warrants	2000000	usd
CY2021Q3	allr	Warrant Excercised Revalued At Blackscholes Model WarrantExcercisedRevaluedAtBlackscholesModel	206000	usd
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	200000000	sek
CY2018Q4	us-gaap	Accounts Payable Interest Bearing Interest Rate AccountsPayableInterestBearingInterestRate	0.02	pure
CY2018Q4	allr	Convertible Shares And Warrants Percentage ConvertibleSharesAndWarrantsPercentage	0.50	pure
CY2019Q2	allr	Committed Tranches Settled Receipt CommittedTranchesSettledReceipt	673000	usd
CY2020Q1	allr	Investor Cash InvestorCash	1000000	usd
CY2020Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	186600	shares
CY2020Q1	allr	Settlement Shares Amount SettlementSharesAmount	2500000	usd
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	79937	shares
CY2020Q1	allr	Settlement Warrants SettlementWarrants	625000	usd
CY2021Q4	allr	Rights Of Warrants RightsOfWarrants	20
CY2022Q4	allr	Shares Of Common Stock SharesOfCommonStock	30000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	allr	Shares Of Preferred Stock SharesOfPreferredStock	500000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	200000	shares
CY2022	us-gaap	Preferred Stock Per Share Amounts Of Preferred Dividends In Arrears PreferredStockPerShareAmountsOfPreferredDividendsInArrears	400
CY2022	allr	Common Stock Description CommonStockDescription	shares of Series B Preferred Stock that have not been redeemed pursuant to an Initial Redemption shall be redeemed in whole, but not in part, (i) if such redemption is ordered by the Board of Directors in its sole discretion, automatically and effective on such time and date specified by the Board of Directors in its sole discretion or (ii) automatically upon the approval by the Company’s stockholders of the Reverse Stock Split and the Share Increase Proposal at any meeting of stockholders held for the purpose of voting on such proposals; andEach share of Series B Preferred Stock redeemed in any Redemption shall be redeemed in consideration for the right to receive an amount equal to $0.01 in cash for each one whole share of Series B Preferred Stock as of the applicable Redemption Time. iii. Issuance of Series B Preferred Stock Dividend Effective December 5, 2022, the Company issued a stock dividend to be distributed as follows to stockholders of record as of close of business on December 5, 2022: (i) 0.016 shares of Series B Preferred Stock for each outstanding share of common stock; and (ii) 1.744 shares of Series B Preferred Stock for each outstanding share of Series A Preferred Stock. Effective February 3, 2023, the Company redeemed 190,786 shares of Series B Preferred stock in exchange for $0.01 per share. iv. Share issuances During the year ended December 31, 2022, the Company issued 7,801,831 common shares valued at $1,156 gross and ($2,265) net of the $3,421 floor price adjustments upon the conversion of 6,214 shares of Series A
CY2021Q4	us-gaap	Shares Issued SharesIssued	2475	shares
CY2021	allr	Common Stock Description CommonStockDescription	(a)295,537 common shares valued at $2,972 upon the exercise of common stock purchase warrants and stock options and the receipt of $2,765 in cash; (b) Units consisting of 2,417,824 common shares and 2,417,824 common share purchase warrants for $5 per unit; valued at $12,125 in exchange for $12,125 in cash, and 482,250 common shares and 482,250 common share purchase units valued at $2,384 in consideration for services. The attached warrants are exercisable for $10 each with an original expiration date of April 15, 2023, subsequently amended to September 13, 2021 (Note 14(b) iii); (c) 628,192 common shares valued at $2,880 upon conversion of debt and payment of accounts payable; and (d) 20,190 common shares valued at $82 upon the conversion of 200 Series A Preferred shares.
CY2021Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	869828	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	388017	shares
CY2021Q3	allr	Options Granted OptionsGranted	156025	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	156025	shares
CY2020Q4	allr	Option To Purchase Common Shares OptionToPurchaseCommonShares	67791	shares
CY2019Q3	allr	Option To Purchase Common Shares OptionToPurchaseCommonShares	112764	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	27017	shares
CY2021	allr	Option To Purchase Common Shares OptionToPurchaseCommonShares	70477	shares
CY2017Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	13924	shares
CY2017Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P36M
CY2016Q1	us-gaap	Incremental Common Shares Attributable To Equity Unit Purchase Agreements IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements	12676	shares
CY2016Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P36M
CY2014Q4	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	570000	shares
CY2014Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.50	pure
CY2015Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.25	pure
CY2021Q3	allr	Issued And Outstanding Options Expired Unexercised IssuedAndOutstandingOptionsExpiredUnexercised	45805	shares
CY2022	us-gaap	Present Value Of Future Insurance Profits Amortization Expense Realized Gain Loss PresentValueOfFutureInsuranceProfitsAmortizationExpenseRealizedGainLoss	1752000	usd
CY2021	us-gaap	Present Value Of Future Insurance Profits Amortization Expense Realized Gain Loss PresentValueOfFutureInsuranceProfitsAmortizationExpenseRealizedGainLoss	6368000	usd
CY2020	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	1156000	usd
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	4203000	usd
CY2022	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	596000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	1003000	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P2Y7M6D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1174992	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.8
CY2022	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2	P4Y10M28D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	46000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.2
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	544042	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.3
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	676949	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.55
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y1M20D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	380119	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	6.46
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y2M26D
CY2022Q4	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions	544042	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.19
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	10.25
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	1328000	usd
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	4223000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	59600000	usd
CY2022Q4	us-gaap	Credit Risk Derivative Liabilities At Fair Value CreditRiskDerivativeLiabilitiesAtFairValue	-374000	usd
CY2022Q4	allr	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Term ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateTerm	P5Y
	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	500000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	5000000	usd
CY2022Q3	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1000000	usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	4000000	usd
CY2022	dei	Document Description DocumentDescription	In consideration of the extended timeframe, and the Company not achieving the minimum patient enrollment, by July 1, 2022, set out in the Second Amendment, the Company is obligated to pay Eisai an extension payment as follows: (i) $100 within 10 days of the execution of the Third Amendment (paid during the period ended September 30, 2022); and (ii) $900 on or before April 1, 2023 (recognized as a milestone expense in the year ended December 31, 2022, and recorded as an accrued development cost liability at December 31, 2022). Once the extension payment is paid in full, the Company shall have until April 1, 2024, to complete enrollment in a further Phase 1b or Phase 2 Clinical Trial of the Product. If the Company has not achieved successful completion of a further Phase 1b or Phase 2 Clinical Trial of the Product prior to April 1, 2024, Eisai may terminate this Agreement in its entirety, in its sole discretion on at least 120 days prior written notice.
CY2022	allr	Sales Milestone Payment SalesMilestonePayment	50000000	usd
CY2022	allr	Licensed Product Sales LicensedProductSales	1000000000	usd
CY2022	allr	Extension Payment ExtensionPayment	1000000000	usd
CY2019Q1	allr	Additional Amount AdditionalAmount	250000	usd
CY2022Q1	allr	Amended License Agreement Description AmendedLicenseAgreementDescription	Pursuant to the terms of the Support Agreement, we agreed (i) to pay to LiPlasome a certain percentage of the Commercialization Proceeds received from Smerud by way of debt cancellation relating to prior work on LiPlaCis® by Smerud, which obligation was to be satisfied by the payment of USD $338 (2,273 thousand DKK) to LiPlasome upon execution of the Support Agreement, (ii) to equally share the milestone payments under the terms of the License Agreement, pursuant to which it was contemplated that upon the achievement of all the milestones, our pro rata share of the Milestone Payments would be up to $3.5 million, (iii) to amend and restate the Original License Agreement, and (iv) to terminate the 2020 Sublicense Agreement as contemplated by the parties pursuant to the terms of the Support Agreement.
CY2020Q2	us-gaap	Development Costs DevelopmentCosts	1264000	usd
CY2022	us-gaap	Distribution Made To Limited Liability Company Llc Member Cash Distributions Declared DistributionMadeToLimitedLiabilityCompanyLLCMemberCashDistributionsDeclared	1309000	usd
CY2022	allr	Company Agreement CompanyAgreement	338000	usd
CY2022Q2	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	338000	usd
CY2022Q2	us-gaap	Debt Instrument Decrease Forgiveness DebtInstrumentDecreaseForgiveness	971000	usd
CY2022Q1	us-gaap	Intercompany Agreements Description IntercompanyAgreementsDescription	i.A one-time upfront payment of $250 and $100 for stenoparib and dovitinib respectively, within 5 business days after January 2, 2022 ($350 received as of April 4, 2022) and recorded in other income as a gain on sale of IP; and ii.two milestone payments of $1 million each due and payable upon receipt of regulatory approval of a product in the United States, and of a product in Europe, respectively.Pursuant to the Oncoheroes Agreement the Company is also entitled to tiered royalties on aggregate net product sales (“Sales”) of between 7% and 12% on net sales of products as follows: 7% on Sales less than $100 million; 10% on Sales of greater than $100 million and less than $200 million; and 12% on Sales greater than $200 million.
CY2022	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-17579000	usd
CY2021	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-26515000	usd
CY2021Q3	us-gaap	Lessor Sales Type Lease Description LessorSalesTypeLeaseDescription	we entered into an Asset Purchase Agreement with Lantern Pharma, Inc. relating to our inventory of Irofulven active pharmaceutical ingredients, our clinical research data relating to Irofulven developed by us during the drug development program under the May 2015 Drug License and Development Agreement for Irofulven and terminated our obligation to further advance the development of Irofulven under the May 2015 agreement. Under the Asset Purchase Agreement, Lantern Pharma agreed to pay us $1 million on closing of the transaction, and additional amounts: (i) when the inventory of Irofulven API is recertified with a longer shelf life; (ii) upon the initiation of treatment of the first patient in an investigator-led “compassionate use” ERCC2/3 mutation subgroup study using Irofulven in certain agreed upon investigators; (iii) upon the initiation of treatment of the first patient within twenty-four months after the closing of the transaction in any human clinical trial of Irofulven initiated by Lantern Pharma; and (iv) upon the initiation of treatment of the second patient within an agreed upon time period after the closing of the transaction in any human clinical trial of Irofulven initiated by Lantern Pharma.
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	459000	usd
CY2022	allr	Loss Before Tax Rate Percentage LossBeforeTaxRatePercentage	0.21	pure
CY2022	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	3692000	usd
CY2021	us-gaap	Foreign Currency Transaction Loss Before Tax ForeignCurrencyTransactionLossBeforeTax	5568000	usd
CY2022	allr	Foreign Rate Differential ForeignRateDifferential	-260000	usd
CY2021	allr	Foreign Rate Differential ForeignRateDifferential	-210000	usd
CY2021	allr	Nondeductible Expenses Sharebased Payments NondeductibleExpensesSharebasedPayments	523000	usd
CY2022	allr	Nondeductible Expenses Other NondeductibleExpensesOther	1000	usd
CY2021	allr	Nondeductible Expenses Other NondeductibleExpensesOther	905000	usd
CY2022	allr	Tax Deduction On Exercise Of Employee Warrants TaxDeductionOnExerciseOfEmployeeWarrants	-3597000	usd
CY2021	allr	Tax Deduction On Exercise Of Employee Warrants TaxDeductionOnExerciseOfEmployeeWarrants	-438000	usd
CY2022	allr	Special Tax Deduction On Research And Development Expenses SpecialTaxDeductionOnResearchAndDevelopmentExpenses	-754000	usd
CY2021	allr	Special Tax Deduction On Research And Development Expenses SpecialTaxDeductionOnResearchAndDevelopmentExpenses	-464000	usd
CY2022	allr	Loss Offset To Research And Development Incentives LossOffsetToResearchAndDevelopmentIncentives	609000	usd
CY2021	allr	Loss Offset To Research And Development Incentives LossOffsetToResearchAndDevelopmentIncentives	682000	usd
CY2022	allr	Other Adjustments OtherAdjustments	1000	usd
CY2021	allr	Other Adjustments OtherAdjustments	60000	usd
CY2022	allr	Adjustment Of Tax Concerning Previous Years AdjustmentOfTaxConcerningPreviousYears	-871000	usd
CY2021	allr	Adjustment Of Tax Concerning Previous Years AdjustmentOfTaxConcerningPreviousYears	134000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	7044000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4322000	usd
CY2021Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	187000	usd
CY2022	allr	Effective Tax Rates EffectiveTaxRates	-1521000	usd
CY2021	allr	Effective Tax Rates EffectiveTaxRates	133000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	113000	usd
CY2022	allr	Deferred Foreign Income Tax Expense DeferredForeignIncomeTaxExpense	-1521000	usd
CY2021	allr	Deferred Foreign Income Tax Expense DeferredForeignIncomeTaxExpense	20000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	133000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	20000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	21000	usd
CY2022Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	1160000	usd
CY2021Q4	us-gaap	Intangible Assets Current IntangibleAssetsCurrent	5198000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1152000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	815000	usd
CY2022Q4	allr	Other Accruals OtherAccruals	44000	usd
CY2021Q4	allr	Other Accruals OtherAccruals	47000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12981000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9095000	usd
CY2022Q4	allr	Total Deferred Tax Income Loss TotalDeferredTaxIncomeLoss	12949000	usd
CY2021Q4	allr	Total Deferred Tax Income Loss TotalDeferredTaxIncomeLoss	4686000	usd
CY2022Q4	allr	Valuation Allowance ValuationAllowance	13298000	usd
CY2021Q4	allr	Valuation Allowance ValuationAllowance	6647000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	349000	usd
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1961000	usd
CY2021	allr	Current Income Tax Expensebenefit CurrentIncomeTaxExpensebenefit	88000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-1521000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20000	usd
CY2021	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	25000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	133000	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	269000	usd
CY2021	us-gaap	Payments For Fees PaymentsForFees	93000	usd
CY2022	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-21052000	usd
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-26648000	usd
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9527111	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6358988	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.21
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-4.19
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	2695907	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	3193950	shares
CY2022	allr	Series A Convertible Preferred Stock SeriesAConvertiblePreferredStock	7406057	shares
CY2021	allr	Series A Convertible Preferred Stock SeriesAConvertiblePreferredStock	1997982	shares
CY2022	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	9071430	shares
CY2022	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	19173394	shares
CY2021	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	5191932	shares
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	2667000	usd
CY2022	us-gaap	Basic Earnings Per Share Pro Forma BasicEarningsPerShareProForma	0.1825
CY2022Q4	allr	Warrant Liability WarrantLiability	374000	usd
CY2021Q4	us-gaap	Assets Held In Trust AssetsHeldInTrust	350000	usd
CY2021Q4	allr	Warrant Liability WarrantLiability	11273000	usd
CY2021Q4	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	7181000	usd
CY2021Q4	us-gaap	Credit Risk Derivative Liabilities At Fair Value CreditRiskDerivativeLiabilitiesAtFairValue	-18454000	usd
CY2022Q4	allr	Warrant Liability WarrantLiability	374000	usd
CY2021Q4	allr	Warrant Liability WarrantLiability	11273000	usd
CY2017Q1	us-gaap	Other Commitments Future Minimum Payments Remainder Of Fiscal Year OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear	500	usd
CY2022	us-gaap	Revenue Recognition Milestone Method Milestone RevenueRecognitionMilestoneMethodMilestone	Pursuant to the agreement, we have agreed to make milestone payments to 2-BBB in connection with the development of 2X-111 by us or our affiliates, or by a third-party (a “Program Acquirer”) that assumes control of the 2X-111 development program from us corresponding to: (i) upon enrollment of the first ten patients required in a Phase 2 clinical trial; (ii) upon the successful completion of a Phase 2 clinical trial; (iii) upon dosing of the first patient in the first Phase 3 clinical trial; (iv) upon submission of the first NDA with the FDA; (v) submission of an MAA to the EMA in the European Union; (vi) upon submission of an NDA in the first of either China or India; (vii) upon receipt of the first authorization by the FDA to market and sell a licensed product; (viii) upon receipt of a MAA for a licensed product in the European Union; and (ix) upon receipt of regulatory approval in the first of either China or India. If all development milestones have been achieved, we may be obligated to pay 2-BBB up to a maximum of $27.75 million which could increase to $55.5 million if 2-BBB successfully expands the field of our license agreement to include all preventative, therapeutic and/or diagnostic uses related to cancer in humans. In addition to the development milestones described above, we have agreed to make a mid-level seven figure one-time payment upon our sales of a licensed product reaching $500 million annually and a low eight figure payment upon the first and second time our sales of a licensed product reaches $1 Billion annual. If all sales milestones have been achieved, we would be obligated to pay 2-BBB up to a maximum of $22.5 million which could increase to $45 million if 2-BBB successfully expands the field of our license agreement to include all preventative, therapeutic and/or diagnostic uses related to cancer in humans.
CY2022	allr	Royalty Payments Description RoyaltyPaymentsDescription	In addition to the milestone payments described above, we have agreed to pay 2-BBB royalties based on annual incremental sales of product derived from 2X-111 in an amount between 5% and 10% of annual sales of between $0 and $100 million, between 6% and 13% of annual sales between $100 million and $250 million, and between 7% and 13% of annual sales in excess of $250 million. We are obligated to pay royalties under the agreement on a product-by-product and country-by-country basis, from the period of time commencing on the first commercial sale of any product in such country and expiring upon the latest of (a) the expiration of the last valid claim of a patent within (i) the 2-BBB intellectual property and/or (ii) the joint intellectual property in such country (if, but only if, such joint intellectual property arose from activities under the clinical development plan), or (b) the 10th anniversary of the date of first commercial sale of such product in such country. However, the agreement may be sooner terminated without cause by us upon 120 days prior written notice, or upon written notice of a material breach of the agreement by 2-BBB that is not cured within 90 days. 2-BBB also has the right to terminate the agreement upon written notice of a material breach of the agreement by us that is not cured within 90 days (30 days for a payment default) or if we file for bankruptcy. 2-BBB also has the right to terminate the agreement in the event we challenge a 2-BBB patent and we have the right to terminate the agreement upon 30 days’ notice for specified safety reasons.
CY2022Q4	allr	Debt Instrument Convertible Conversion Price DebtInstrumentConvertibleConversionPrice	0.037
CY2022	allr	Expiration Of The Allowable Price Percentage ExpirationOfTheAllowablePricePercentage	0.02	pure
CY2022	allr	Partial Liquid Damage Interest Rate PartialLiquidDamageInterestRate	0.18	pure
CY2022	us-gaap	Subsequent Event Description SubsequentEventDescription	(1) to approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares from 30,500,000 to 750,500,000, and to increase the number of our common stock from 30,000,000 to 750,000,000, in substantially the form attached to the Proxy Statement as Appendix A (the “Share Increase Proposal”); and (2) to approve an amendment to our Certificate of Incorporation, as amended, in substantially the form attached to the Proxy Statement as Appendix B, to, at the discretion of the Board of Directors of the Company (the “Board”), effect a reverse stock split with respect to the Company’s issued and outstanding common stock, par value $0.0001 per share, at a ratio between 1-for-20 and 1-for-35 (the “Range”), with the ratio within such Range to be determined at the discretion of the Board (the “Reverse Stock Split Proposal”) and included in a public announcement. Under the terms of the Series C Preferred Stock, the holders thereof may only vote on Proposal 1 (Share Increase Proposal) and Proposal 2 (Reverse Stock Split Proposal) and for no other matters. Each holder of one share of Series C Preferred Stock is entitled to 620 votes representing 31,000,000 votes in the aggregate assuming 50,000 shares of Series C Preferred Stock is outstanding.
CY2022Q4	us-gaap	Net Investment In Lease Current NetInvestmentInLeaseCurrent		usd
CY2021Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021	allr	Deemed Dividend Percentage1 DeemedDividendPercentage1		pure
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9527111	shares
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts		usd
CY2021	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock		usd
CY2021	allr	Penalty On Series A Preferred Stock Liability1 PenaltyOnSeriesAPreferredStockLiability1		usd
CY2022	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt		usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2021	allr	Gain On Sale Of Ip GainOnSaleOfIP		usd
CY2021	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2022	us-gaap	Stock Issued1 StockIssued1		usd
CY2022	allr	Conversion Of Derivative Liability To Equity ConversionOfDerivativeLiabilityToEquity		usd
CY2021	allr	Deemed8 Dividend On Series A Preferred Shares Deemed8DividendOnSeriesAPreferredShares		usd
CY2021	allr	Series B Preferred Share Dividend SeriesBPreferredShareDividend		usd
CY2022	allr	Noncash Derivative Warrant Liability Costs NoncashDerivativeWarrantLiabilityCosts		usd
CY2022	allr	Right Of Use Asset Modification RightOfUseAssetModification		usd
CY2021Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2021	allr	Deferred Directors Officers Insurance Expense DeferredDirectorsOfficersInsuranceExpense		usd
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets		usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue		usd
CY2021Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability		usd
CY2022Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities		usd
CY2022	allr	Fair Value Per Warrant Issuable FairValuePerWarrantIssuable
CY2020Q4	us-gaap	Derivative Credit Risk Valuation Adjustment Derivative Liabilities DerivativeCreditRiskValuationAdjustmentDerivativeLiabilities		usd
CY2021	allr	Translation Effect TranslationEffect		usd
CY2021	allr	Loss Before Tax Rate Percentage LossBeforeTaxRatePercentage	0.220	pure
CY2022	allr	Nondeductible Expenses Sharebased Payments NondeductibleExpensesSharebasedPayments		usd
CY2022Q4	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts		usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent		usd
CY2022	allr	Current Income Tax Expensebenefit CurrentIncomeTaxExpensebenefit		usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes		usd
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6358988	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9527111	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.21
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-4.19
CY2021	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1		shares
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001860657

Files In Submission

Name	View Source	Status
0001213900-23-019295-index-headers.html	Edgar Link	pending
0001213900-23-019295-index.html	Edgar Link	pending
0001213900-23-019295.txt	Edgar Link	pending
0001213900-23-019295-xbrl.zip	Edgar Link	pending
allr-20221231.xsd	Edgar Link	pending
allr-20221231_cal.xml	Edgar Link	unprocessable
f10k2022ex10-32_allarity.htm	Edgar Link	pending
f10k2022ex10-35_allarity.htm	Edgar Link	pending
f10k2022ex21-1_allarity.htm	Edgar Link	pending
f10k2022ex31-1_allarity.htm	Edgar Link	pending
f10k2022ex31-2_allarity.htm	Edgar Link	pending
f10k2022ex32-1_allarity.htm	Edgar Link	pending
f10k2022ex32-2_allarity.htm	Edgar Link	pending
f10k2022ex4vi_allarity.htm	Edgar Link	pending
f10k2022_allaritytherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
image_020.jpg	Edgar Link	pending
image_021.jpg	Edgar Link	pending
image_022.jpg	Edgar Link	pending
image_023.jpg	Edgar Link	pending
image_024.jpg	Edgar Link	pending
image_025.jpg	Edgar Link	pending
image_027.jpg	Edgar Link	pending
image_028.jpg	Edgar Link	pending
image_029.jpg	Edgar Link	pending
image_030.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
allr-20221231_lab.xml	Edgar Link	unprocessable
allr-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_allaritytherap_htm.xml	Edgar Link	completed
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
allr-20221231_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLR
Allarity Therapeutics, Inc. Stock $allr

2023 Q1 Form 10-K Financial Statement

#000121390023019295 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLR Allarity Therapeutics, Inc. Stock $allr

2023 Q1 Form 10-K Financial Statement

#000121390023019295 Filed on March 13, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLR
Allarity Therapeutics, Inc. Stock $allr